New adjuvants for human vaccines.

[1]  G. Leroux-Roels,et al.  Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. , 2010, Vaccine.

[2]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[3]  D. Harper.  Currently approved prophylactic HPV vaccines , 2009, Expert review of vaccines.

[4]  Arnaud M. Didierlaurent,et al.  AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1 , 2009, The Journal of Immunology.

[5]  M. Demoitié,et al.  A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon , 2009, PloS one.

[6]  M. Knuf,et al.  Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. , 2009, Vaccine.

[7]  T. Vesikari,et al.  MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. , 2009, Vaccine.

[8]  I. Carletti,et al.  Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years , 2009, Human vaccines.

[9]  Philippa Marrack,et al.  Alum Induces Innate Immune Responses through Macrophage and Mast Cell Sensors, But These Sensors Are Not Required for Alum to Act As an Adjuvant for Specific Immunity1 , 2009, The Journal of Immunology.

[10]  Rino Rappuoli,et al.  Vaccinology in the genome era. , 2009, The Journal of clinical investigation.

[11]  A. Shahzad,et al.  Inactivated Polio Vaccine (IPV): a strong candidate vaccine for achieving global polio eradication program. , 2009, Vaccine.

[12]  C. Coban,et al.  Innate immune control of nucleic acid-based vaccine immunogenicity , 2009, Expert review of vaccines.

[13]  G. Leroux-Roels.  Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data , 2009, Expert opinion on biological therapy.

[14]  J. Dietrich,et al.  Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose , 2009, PloS one.

[15]  Ennio De Gregorio,et al.  The path to a successful vaccine adjuvant--'the long and winding road'. , 2009, Drug discovery today.

[16]  M. Zambon,et al.  Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine , 2009, Proceedings of the National Academy of Sciences.

[17]  P. Marrack,et al.  Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.

[18]  Volker Brauer,et al.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels , 2009, Proceedings of the National Academy of Sciences.

[19]  Volker Brauer,et al.  MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults , 2009, PloS one.

[20]  H. Hammad,et al.  Mechanism of action of clinically approved adjuvants. , 2009, Current opinion in immunology.

[21]  M. Demoitié,et al.  Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. , 2008, The New England journal of medicine.

[22]  Shizuo Akira,et al.  Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines , 2008, Proceedings of the National Academy of Sciences.

[23]  H. Hammad,et al.  Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome , 2008, The Journal of Immunology.

[24]  Rino Rappuoli,et al.  Alum adjuvanticity: Unraveling a century old mystery , 2008, European journal of immunology.

[25]  G. Núñez,et al.  The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated IL‐1β secretion but dispensable for adjuvant activity , 2008, European journal of immunology.

[26]  R. Rappuoli,et al.  Molecular and cellular signatures of human vaccine adjuvants , 2008, Proceedings of the National Academy of Sciences.

[27]  F. Re,et al.  Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP31 , 2008, The Journal of Immunology.

[28]  Michael Gale,et al.  Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA , 2008, Nature.

[29]  Richard A. Flavell,et al.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.

[30]  Mariagrazia Pizza,et al.  The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1 , 2008, The Journal of Immunology.

[31]  C. Bokemeyer,et al.  Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming , 2008, Proceedings of the National Academy of Sciences.

[32]  R. K. Evans,et al.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. , 2008, Vaccine.

[33]  C. Cooper,et al.  Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy , 2007, Expert opinion on biological therapy.

[34]  F. Zepp,et al.  Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. , 2007, Human immunology.

[35]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[36]  J. Ruland,et al.  Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17 , 2007, Nature Immunology.

[37]  Y. Huang,et al.  Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. , 2007, Vaccine.

[38]  O. Levy,et al.  Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. , 2006, Blood.

[39]  Brigitte Colau,et al.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.

[40]  Shizuo Akira,et al.  IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. , 2006, Vaccine.

[41]  E. Agger,et al.  Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. , 2006, Vaccine.

[42]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[43]  Bali Pulendran,et al.  Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity , 2006, The Journal of experimental medicine.

[44]  R. Koup,et al.  HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Francesco Bertoni,et al.  Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells , 2005, Nature Immunology.

[46]  Ross M. Kedl,et al.  Immunization with HIV-1 Gag Protein Conjugated to a TLR7/8 Agonist Results in the Generation of HIV-1 Gag-Specific Th1 and CD8+ T Cell Responses , 2005, The Journal of Immunology.

[47]  J. Paul Robinson,et al.  Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. , 2005, Vaccine.

[48]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[49]  V. Schijns,et al.  Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. , 2003, Vaccine.

[50]  A. Podda.  The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. , 2001, Vaccine.

[51]  D. McDonald,et al.  Dendritic cells internalize vaccine adjuvant after intramuscular injection. , 1998, Cellular immunology.

[52]  P. van Damme,et al.  Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. , 1998, Vaccine.

[53]  N. Goto,et al.  Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. , 1997, Vaccine.

[54]  N. Goto,et al.  Histopathological Studies of Reactions in Mice Injected with Aluminum‐Adsorbed Tetanus Toxoid , 1982, Microbiology and immunology.